{
    "2020-06-15": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Abbott Gains FDA Nod For A New Diabetes Device, But Dexcom Rockets",
                "features": {
                    "keywords": [
                        "FDA",
                        "Nod",
                        "Diabetes",
                        "Device",
                        "Dexcom"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Abbott Gains New Clearance As Devices Rivalry With Dexcom Builds",
                "features": {
                    "keywords": [
                        "Abbott",
                        "Clearance",
                        "Devices",
                        "Rivalry",
                        "Dexcom"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Is Abbott Stock A Buy As Worries Of A Second Coronavirus Wave Spread?",
                "features": {
                    "keywords": [
                        "Abbott",
                        "Stock",
                        "Buy",
                        "Coronavirus",
                        "Wave"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "FDA clears new version of Abbott's diabetes glucose monitor",
                "features": {
                    "keywords": [
                        "FDA",
                        "clears",
                        "version",
                        "Abbott",
                        "diabetes",
                        "glucose",
                        "monitor"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Abbott's (ABT) FreeStyle Libre Study Outcome Favorable",
                "features": {
                    "keywords": [
                        "Abbott",
                        "FreeStyle",
                        "Libre",
                        "Study",
                        "Outcome",
                        "Favorable"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Abbott's Bluetooth-Enabled Glucose Monitor Finally Clears FDA Hurdle",
                "features": {
                    "keywords": [
                        "Bluetooth-Enabled",
                        "Glucose",
                        "Monitor",
                        "FDA",
                        "Hurdle"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "U.S. FDA clears new version of Abbott's low-cost glucose monitor",
                "features": {
                    "keywords": [
                        "U.S.",
                        "FDA",
                        "clears",
                        "version",
                        "Abbott",
                        "low-cost",
                        "glucose",
                        "monitor"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor",
                "features": {
                    "keywords": [
                        "U.S.",
                        "FDA",
                        "clears",
                        "version",
                        "2.0",
                        "Abbott",
                        "low-cost",
                        "glucose",
                        "monitor"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards",
                "features": {
                    "keywords": [
                        "Abbott",
                        "FreeStyle®",
                        "Libre",
                        "2",
                        "iCGM",
                        "Cleared",
                        "U.S.",
                        "Adults",
                        "Children",
                        "Diabetes",
                        "Accuracy",
                        "Performance",
                        "Standards"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "medical devices"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}